

Maurizio Ricci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4011226/publications.pdf>

Version: 2024-02-01

103
papers

4,033
citations

94433

37
h-index

133252

59
g-index

106
all docs

106
docs citations

106
times ranked

5371
citing authors

#	ARTICLE	IF	CITATIONS
1	Bioadhesive patches based on carboxymethyl cellulose/polyvinylpyrrolidone/bentonite composites and Soluplus® for skin administration of poorly soluble molecules. <i>Applied Clay Science</i> , 2022, 216, 106377.	5.2	7
2	Wound Dressing: Combination of Acacia Gum/PVP/Cyclic Dextrin in Bioadhesive Patches Loaded with Grape Seed Extract. <i>Pharmaceutics</i> , 2022, 14, 485.	4.5	12
3	Pharmaceutically Active Microbial AhR Agonists as Innovative Biodrugs in Inflammation. <i>Pharmaceutics</i> , 2022, 15, 336.	3.8	5
4	Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite. , 2022, 10, e003725.		39
5	MgAl and ZnAl-Hydroxaluminates as Materials for Cosmetic and Pharmaceutical Formulations: Study of Their Cytotoxicity on Different Cell Lines. <i>Pharmaceutics</i> , 2022, 15, 784.	3.8	5
6	Taxifolin stability: In silico prediction and in vitro degradation with HPLC-UV/UPLC-ESI-MS monitoring. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 232-240.	5.3	12
7	Development and Characterization of Xanthan Gum and Alginate Based Bioadhesive Film for Pycnogenol Topical Use in Wound Treatment. <i>Pharmaceutics</i> , 2021, 13, 324.	4.5	25
8	Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics. <i>Pharmaceutics</i> , 2021, 13, 494.	4.5	3
9	Indole-3-Carboxaldehyde Restores Gut Mucosal Integrity and Protects from Liver Fibrosis in Murine Sclerosing Cholangitis. <i>Cells</i> , 2021, 10, 1622.	4.1	23
10	Development of sodium carboxymethyl cellulose based polymeric microparticles for in situ hydrogel wound dressing formation. <i>International Journal of Pharmaceutics</i> , 2021, 602, 120606.	5.2	18
11	Enteric formulated indole-3-carboxaldehyde targets the aryl hydrocarbon receptor for protection in a murine model of metabolic syndrome. <i>International Journal of Pharmaceutics</i> , 2021, 602, 120610.	5.2	22
12	Targeted Drug Delivery Technologies Potentiate the Overall Therapeutic Efficacy of an Indole Derivative in a Mouse Cystic Fibrosis Setting. <i>Cells</i> , 2021, 10, 1601.	4.1	15
13	Emulgel Loaded with Flaxseed Extracts as New Therapeutic Approach in Wound Treatment. <i>Pharmaceutics</i> , 2021, 13, 1107.	4.5	12
14	Development and in vitro-in vivo performances of an inhalable indole-3-carboxaldehyde dry powder to target pulmonary inflammation and infection. <i>International Journal of Pharmaceutics</i> , 2021, 607, 121004.	5.2	9
15	Hazelnut Shells as Source of Active Ingredients: Extracts Preparation and Characterization. <i>Molecules</i> , 2021, 26, 6607.	3.8	13
16	Exploring Taxifolin Polymorphs: Insights on Hydrate and Anhydrous Forms. <i>Pharmaceutics</i> , 2021, 13, .	4.5	0
17	Exploring Taxifolin Polymorphs: Insights on Hydrate and Anhydrous Forms. <i>Pharmaceutics</i> , 2021, 13, 1328.	4.5	6
18	Development and characterization of mucoadhesive-thermoreponsive gels for the treatment of oral mucosa diseases. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 142, 105125.	4.0	37

#	ARTICLE	IF	CITATIONS
19	Polymeric Bioadhesive Patch Based on Ketoprofen-Hydrocortisone Hybrid for Local Treatments. <i>Pharmaceutics</i> , 2020, 12, 733.	4.5	9
20	Preparation and characterization of polymeric microparticles loaded with <i>Moringa oleifera</i> leaf extract for exuding wound treatment. <i>International Journal of Pharmaceutics</i> , 2020, 587, 119700.	5.2	22
21	Improved Achiral and Chiral HPLC-UV Analysis of Ruxolitinib in Two Different Drug Formulations. <i>Separations</i> , 2020, 7, 47.	2.4	7
22	Biocompatible alginate silica supported silver nanoparticles composite films for wound dressing with antibiofilm activity. <i>Materials Science and Engineering C</i> , 2020, 112, 110863.	7.3	60
23	Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?. <i>Pharmaceutics</i> , 2020, 12, 624.	4.5	20
24	Bioadhesive Polymeric Films Based on Red Onion Skins Extract for Wound Treatment: An Innovative and Eco-Friendly Formulation. <i>Molecules</i> , 2020, 25, 318.	3.8	30
25	Flow nanoprecipitation of size-controlled D-leucine nanoparticles for spray-drying formulations. <i>Reaction Chemistry and Engineering</i> , 2019, 4, 1861-1868.	3.7	1
26	Development and Characterization of New Topical Hydrogels Based on Alpha Lipoic Acid-Hydrocortisone Hybrids. <i>Cosmetics</i> , 2019, 6, 35.	3.3	13
27	D-leucine microparticles as an excipient to improve the aerosolization performances of dry powders for inhalation. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 130, 54-64.	4.0	14
28	A Novel Stabilizing Approach to Improve the Manufacturing of Biodegradable Microparticles Entrapping Plasticizing Active Molecules: the Case of 4-Methoxychalcone. <i>Journal of Pharmaceutical Innovation</i> , 2019, 14, 159-175.	2.4	1
29	Meeting the unmet: from traditional to cutting-edge techniques for poly lactide and poly lactide-co-glycolide microparticle manufacturing. <i>Journal of Pharmaceutical Investigation</i> , 2019, 49, 381-404.	5.3	44
30	Bioadhesive polymeric films based on usnic acid for burn wound treatment: Antibacterial and cytotoxicity studies. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 178, 488-499.	5.0	37
31	Exploring the Nano Spray-Drying Technology as an Innovative Manufacturing Method for Solid Lipid Nanoparticle Dry Powders. <i>AAPS PharmSciTech</i> , 2019, 20, 19.	3.3	9
32	Folic acid-layered double hydroxides hybrids in skin formulations: Technological, photochemical and in vitro cytotoxicity on human keratinocytes and fibroblasts. <i>Applied Clay Science</i> , 2019, 168, 382-395.	5.2	35
33	Biodegradable composite porous poly(DL-lactide-co-L-glycolide) scaffold supports mesenchymal stem cell differentiation and calcium phosphate deposition. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 219-229.	2.8	17
34	Artificial apolipoprotein corona enables nanoparticle brain targeting. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 429-438.	3.3	63
35	Towards Targeting the Aryl Hydrocarbon Receptor in Cystic Fibrosis. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	3.0	24
36	Development of Novel Indole-3-Aldehyde-Loaded Gastro-Resistant Spray-Dried Microparticles for Postbiotic Small Intestine Local Delivery. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 2341-2353.	3.3	28

#	ARTICLE	IF	CITATIONS
37	Reshaping antibiotics through hydrophobic drug-bile acid ionic complexation enhances activity against <i>Staphylococcus aureus</i> biofilms. <i>International Journal of Pharmaceutics</i> , 2017, 528, 144-162.	5.2	10
38	Montmorillonite-chitosan-chlorhexidine composite films with antibiofilm activity and improved cytotoxicity for wound dressing. <i>Journal of Colloid and Interface Science</i> , 2017, 491, 265-272.	9.4	70
39	The long and winding road to inhaled TB therapy: not only the bug's fault. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 347-363.	2.0	15
40	The strategic relevance of manufacturing technology: An overall quality concept to promote innovation preventing drug shortage. <i>International Journal of Pharmaceutics</i> , 2017, 516, 144-157.	5.2	14
41	Alginate beads as a carrier for omeprazole/SBA-15 inclusion compound: A step towards the development of personalized paediatric dosage forms. <i>Carbohydrate Polymers</i> , 2015, 133, 464-472.	10.2	23
42	Dynamic behavior of a spring-powered micronozzle needle-free injector. <i>International Journal of Pharmaceutics</i> , 2015, 491, 91-98.	5.2	34
43	Chlorhexidine-loaded functionalized mesoporous MCM-41 poly(methylmethacrylate) based composites with <i>Candida</i> antibiofilm activity. <i>RSC Advances</i> , 2015, 5, 84827-84835.	3.6	6
44	Drug delivery system innovation and Health Technology Assessment: Upgrading from Clinical to Technological Assessment. <i>International Journal of Pharmaceutics</i> , 2015, 495, 1005-1018.	5.2	14
45	Powder, capsule and device: An imperative <i>m</i> <i>à</i> <i>trois</i> for respirable dry powders. <i>International Journal of Pharmaceutics</i> , 2015, 494, 40-48.	5.2	18
46	β -cyclodextrin hinders PLGA plasticization during microparticle manufacturing. <i>Journal of Drug Delivery Science and Technology</i> , 2015, 30, 375-383.	3.0	10
47	The Influence of Feedstock and Process Variables on the Encapsulation of Drug Suspensions by Spray-Drying in Fast Drying Regime: The Case of Novel Antitubercular Drug-Palladium Complex Containing Polymeric Microparticles. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1255-1268.	3.3	18
48	Chitosan films containing mesoporous SBA-15 supported silver nanoparticles for wound dressing. <i>Journal of Materials Chemistry B</i> , 2014, 2, 6054.	5.8	75
49	Capreomycin inhalable powders prepared with an innovative spray-drying technique. <i>International Journal of Pharmaceutics</i> , 2014, 469, 132-139.	5.2	31
50	Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin-palladium complex. <i>International Journal of Pharmaceutics</i> , 2013, 440, 273-282.	5.2	58
51	Capreomycin supergenerics for pulmonary tuberculosis treatment: Preparation, in vitro, and in vivo characterization. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 83, 388-395.	4.3	43
52	Conformal polymer coatings for pancreatic islets transplantation. <i>International Journal of Pharmaceutics</i> , 2013, 440, 141-147.	5.2	16
53	Mesoporous Silicate MCM-41 as a Particulate Carrier for Octyl Methoxycinnamate: Sunscreen Release and Photostability. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 1468-1475.	3.3	39
54	Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. <i>International Journal of Pharmaceutics</i> , 2013, 454, 316-323.	5.2	45

#	ARTICLE	IF	CITATIONS
55	Lipid nanoparticles for brain targeting II. Technological characterization. <i>Colloids and Surfaces B: Biointerfaces</i> , 2013, 110, 130-137.	5.0	32
56	Oxybenzone Entrapped in Mesoporous Silicate MCM-41. <i>Journal of Pharmaceutical Innovation</i> , 2013, 8, 212-217.	2.4	13
57	Synthesis, characterization and <i>in vitro</i> extracellular and intracellular activity against <i>Mycobacterium tuberculosis</i> infection of new second-line antitubercular drug-palladium complexes. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 66, 106-121.	2.4	19
58	Response to Comment on Blasi et al. (2011) "Lipid nanoparticles for brain targeting I. Formulation optimization". <i>International Journal of Pharmaceutics</i> , 2012, 439, 171-174.	5.2	0
59	Montmorillonite as an agent for drug photostability. <i>Journal of Materials Chemistry</i> , 2012, 22, 22743.	6.7	25
60	Use of SBA-15 for furosemide oral delivery enhancement. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 46, 43-48.	4.0	60
61	MCM-41 for furosemide dissolution improvement. <i>Microporous and Mesoporous Materials</i> , 2012, 147, 343-349.	4.4	66
62	Lipid nanoparticles for brain targeting I. Formulation optimization. <i>International Journal of Pharmaceutics</i> , 2011, 419, 287-295.	5.2	48
63	The real value of novel particulate carriers for sunscreen formulation. <i>Expert Review of Dermatology</i> , 2011, 6, 509-517.	0.3	16
64	Bioactive Long-Term Release from Biodegradable Microspheres Preserves Implanted ALG-PLO-ALG Microcapsules from In Vivo Response to Purified Alginate. <i>Pharmaceutical Research</i> , 2010, 27, 285-295.	3.5	13
65	Simple and scalable method for peptide inhalable powder production. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 39, 53-58.	4.0	25
66	Development of a scalable procedure for fine calcium alginate particle preparation. <i>Chemical Engineering Journal</i> , 2010, 160, 363-369.	12.7	54
67	Lipid Nanoparticles for Drug Delivery to the Brain: <i>In Vivo Veritas</i> . <i>Journal of Biomedical Nanotechnology</i> , 2009, 5, 344-350.	1.1	16
68	Novel composite microparticles for protein stabilization and delivery. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 36, 226-234.	4.0	54
69	Fighting tuberculosis: old drugs, new formulations. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 977-993.	5.0	38
70	Chitosan and a modified chitosan as agents to improve performances of mucoadhesive vaginal gels. <i>Colloids and Surfaces B: Biointerfaces</i> , 2008, 66, 141-145.	5.0	69
71	Physicochemical characterization and release mechanism of a novel prednisone biodegradable microsphere formulation. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 303-317.	3.3	28
72	Role of mesoporous silicates on carbamazepine dissolution rate enhancement. <i>Microporous and Mesoporous Materials</i> , 2008, 113, 445-452.	4.4	64

#	ARTICLE	IF	CITATIONS
73	Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. International Journal of Pharmaceutics, 2008, 357, 295-304.	5.2	229
74	Influence of Compression Force on The Behavior of Mucoadhesive Buccal Tablets. AAPS PharmSciTech, 2008, 9, 274-281.	3.3	20
75	Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. International Journal of Pharmaceutics, 2007, 333, 103-111.	5.2	69
76	Solid lipid nanoparticles for targeted brain drug delivery. Advanced Drug Delivery Reviews, 2007, 59, 454-477.	13.7	432
77	Ketoprofen poly(lactide-co-glycolide) physical interaction. AAPS PharmSciTech, 2007, 8, E78-E85.	3.3	76
78	Anionic clays for sunscreen agent safe use: Photoprotection, photostability and prevention of their skin penetration. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 62, 185-193.	4.3	96
79	Development of liposomal capreomycin sulfate formulations: Effects of formulation variables on peptide encapsulation. International Journal of Pharmaceutics, 2006, 311, 172-181.	5.2	52
80	Preparation and in vitro and in vivo characterization of composite microcapsules for cell encapsulation. International Journal of Pharmaceutics, 2006, 324, 27-36.	5.2	31
81	Analytical characterization of a ferulic acid/ β -cyclodextrin inclusion complex. Journal of Pharmaceutical and Biomedical Analysis, 2006, 40, 875-881.	2.8	64
82	Evaluation and Optimization of the Conditions for an Improved Ferulic Acid Intercalation into a Synthetic Lamellar Anionic Clay. Pharmaceutical Research, 2006, 23, 604-613.	3.5	7
83	Delivering Drugs to the Central Nervous System: A Medicinal Chemistry or a Pharmaceutical Technology Issue?. Current Medicinal Chemistry, 2006, 13, 1757-1775.	2.4	48
84	Long-term delivery of superoxide dismutase and catalase entrapped in poly(lactide-co-glycolide) microspheres: In vitro effects on isolated neonatal porcine pancreatic cell clusters. Journal of Controlled Release, 2005, 107, 65-77.	9.9	56
85	Ketoprofen controlled release from composite microcapsules for cell encapsulation: Effect on post-transplant acute inflammation. Journal of Controlled Release, 2005, 107, 395-407.	9.9	83
86	Evaluation of Indomethacin Percutaneous Absorption from Nanostructured Lipid Carriers (NLC): In Vitro and In Vivo Studies. Journal of Pharmaceutical Sciences, 2005, 94, 1149-1159.	3.3	102
87	Novel mucoadhesive buccal formulation containing metronidazole for the treatment of periodontal disease. Journal of Controlled Release, 2004, 95, 521-533.	9.9	153
88	Development of mucoadhesive patches for buccal administration of ibuprofen. Journal of Controlled Release, 2004, 99, 73-82.	9.9	208
89	Biodegradable microspheres as carriers for native superoxide dismutase and catalase delivery. AAPS PharmSciTech, 2004, 5, 1-9.	3.3	66
90	Leucinostatin-A loaded nanospheres: characterization and in vivo toxicity and efficacy evaluation. International Journal of Pharmaceutics, 2004, 275, 61-72.	5.2	25

#	ARTICLE	IF	CITATIONS
91	UV spectroscopy and reverse-phase HPLC as novel methods to determine Capreomycin of liposomal fomulations. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 36, 249-255.	2.8	22
92	Potential prodrugs of non-steroidal anti-inflammatory agents for targeted drug delivery to the CNS. <i>European Journal of Medicinal Chemistry</i> , 2004, 39, 715-727.	5.5	41
93	Unilamellar vesicles as potential capreomycin sulfate carriers: Preparation and physicochemical characterization. <i>AAPS PharmSciTech</i> , 2003, 4, 549-560.	3.3	22
94	New Oligoethylene Ester Derivatives of 5â€²-iodo-2â€²-deoxyuridine as Dermal Prodrugs: Synthesis, Physicochemical Properties, and Skin Permeation Studies. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 171-179.	3.3	11
95	Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations. <i>International Journal of Pharmaceutics</i> , 2001, 228, 79-87.	5.2	48
96	Improved function of rat islets upon co-microencapsulation with Sertoli's cells in alginate/poly-L-ornithine. <i>AAPS PharmSciTech</i> , 2001, 2, 48-54.	3.3	34
97	Antimicrobial Nonapeptide Leucinostatin A-Dependent Effects on the Physical Properties of Phospholipid Model Membranes. <i>Journal of Colloid and Interface Science</i> , 2000, 226, 222-230.	9.4	39
98	Liposome-based formulations for the antibiotic nonapeptide Leucinostatin A: Fourier transform infrared spectroscopy characterization and in vivo toxicologic study. <i>AAPS PharmSciTech</i> , 2000, 1, 9-19.	3.3	3
99	Liposome-based formulations for the antibiotic nonapeptide Leucinostatin A: Fourier transform infrared spectroscopy characterization and in vivo toxicologic study. <i>AAPS PharmSciTech</i> , 2000, 1, 9-19.	3.3	4
100	Antibody-targeted leucinostatin A. <i>Journal of Controlled Release</i> , 1994, 32, 37-44.	9.9	2
101	The nonapeptide leucinostatin A acts as a weak ionophore and as an immunosuppressant on T lymphocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1994, 1221, 125-132.	4.1	31
102	Leucinostatin D. A novel peptide antibiotic from <i>Paecilomyces marquandii</i> . <i>Journal of Antibiotics</i> , 1987, 40, 130-133.	2.0	42
103	Leucinostatins H and K, two novel peptide antibiotics with tertiary amine-oxide terminal group from <i>Paecilomyces marquandii</i> Isolation, structure and biological activity.. <i>Journal of Antibiotics</i> , 1987, 40, 714-716.	2.0	39